Influence of interleukin polymorphisms on development of gastric cancer and peptic ulcer

Table 9 ORs for the development of gastric non-cardia cancer with the IL-6-174, +572, +597 and +634 polymorphisms

	Genotype	1NUD (n)	Cancer (n)	OR	95% CI	P value	Ulcer (n)	OR	95% CI	P value
IL-6-174	C/C	126	34	-			1
	C/G	310	82	0.98	0.63-1.54	0.93	26	10.57	1.42-78.73	0.02
	G/G	261	142	2.02	1.31-3.10	< 0.01	124	59.86	8.27-433.4	< 0.01
	G carrier	571	224	1.45	0.97-2.19	0.06	150	33.10	4.59-238.8	< 0.01
IL-6+572	C/C	177	173	-			327	-
	C/G	143	143	1.02	0.75-1.40	0.89	214	0.81	0.61-1.07	0.15
	G/G	20	29	1.48	0.81-2.72	0.20	44	1.19	0.68-2.08	0.54
	G carrier	163	172	1.08	0.80-1.46	0.61	258	0.86	0.66-1.12	0.26
IL-6+597	G/G	102	75	-				-
	G/A	102	67	0.89	0.58-1.37	0.61
	A/A	61	28	0.62	0.37-1.07	0.09
	A carrier	163	95	0.79	0.54-1.17	0.24
IL-6+634	C/C	118	96	-
	C/T	84	55	0.81	0.52-1.24	0.33
	T/T	9	4	0.45	0.16-1.83	0.32
	T carrier	93	59	0.78	0.51-1.12	0.25

¹NUD includes patients with gastritis without gastric cancer and peptic ulcer, and atrophic gastritis. Because we deleted a number of gastric cardia cancer patients, the number of cancer patients shown in this Table does not match that in Table 3.